Intuitive Surgical, Inc. (NASDAQ:ISRG) Stake Increased by Elite Wealth Management Inc.

Elite Wealth Management Inc. grew its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.2% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 24,339 shares of the medical equipment provider’s stock after buying an additional 45 shares during the quarter. Intuitive Surgical makes up about 0.4% of Elite Wealth Management Inc.’s investment portfolio, making the stock its 9th largest holding. Elite Wealth Management Inc.’s holdings in Intuitive Surgical were worth $10,827,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Ridgewood Investments LLC purchased a new position in shares of Intuitive Surgical during the 2nd quarter worth $26,000. Creekmur Asset Management LLC raised its position in Intuitive Surgical by 200.0% during the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 42 shares during the period. LGT Financial Advisors LLC lifted its holdings in Intuitive Surgical by 415.4% during the 2nd quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 54 shares in the last quarter. Delos Wealth Advisors LLC grew its position in shares of Intuitive Surgical by 380.0% during the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 57 shares in the last quarter. Finally, LRI Investments LLC purchased a new stake in shares of Intuitive Surgical in the 1st quarter worth approximately $30,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Up 1.6 %

Shares of NASDAQ:ISRG opened at $490.01 on Friday. The business has a 50 day moving average of $467.17 and a 200-day moving average of $424.26. The stock has a market cap of $173.81 billion, a PE ratio of 88.45, a P/E/G ratio of 5.41 and a beta of 1.39. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $496.18.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. The firm had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.18 EPS. Equities research analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Robert Desantis sold 188 shares of the business’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $482.21, for a total value of $90,655.48. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,655,048.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, EVP Robert Desantis sold 188 shares of the company’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $482.21, for a total transaction of $90,655.48. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,655,048.26. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Amy L. Ladd sold 450 shares of the stock in a transaction on Friday, September 13th. The shares were sold at an average price of $490.28, for a total value of $220,626.00. Following the completion of the transaction, the director now owns 821 shares of the company’s stock, valued at $402,519.88. The disclosure for this sale can be found here. Insiders have sold 53,120 shares of company stock worth $25,528,753 over the last ninety days. Corporate insiders own 0.90% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ISRG. Barclays raised their price objective on Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research note on Thursday, July 18th. Morgan Stanley increased their price objective on Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Truist Financial upped their price objective on shares of Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a report on Tuesday, July 16th. The Goldman Sachs Group assumed coverage on shares of Intuitive Surgical in a research note on Thursday, May 30th. They set a “buy” rating and a $500.00 target price on the stock. Finally, BTIG Research raised their price target on Intuitive Surgical from $469.00 to $494.00 and gave the company a “buy” rating in a research note on Wednesday, August 28th. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $446.45.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.